



BIO Digital Presentation

Dr. Steven Gourlay MBBS FRACP PhD MBA: CEO & MD

June 2021

Disclaimer

This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

This presentation is not for general distribution or third party reliance or use.

This presentation contains certain budget information, forecasts and forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management in respect of which there is **NO guarantee of future performance**. Such budget information, forecasts and forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. These risks and uncertainties include, but are not limited to the performance of Actinogen in its clinical trials including whether it's technology proves to be a safe and effective treatment, market penetration, competition from any other similar products, intellectual property risks (including securing rights in technology and patents) and global economic conditions. Furthermore, Actinogen's research, product development, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. There is no guarantee that Actinogen will obtain the required approvals, licences and registrations from the relevant authorities in jurisdictions in which it operates. Actinogen or others could identify product and efficacy issues relating to the safety of our technology. Accordingly, all forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. There is no guarantee that Actinogen will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward looking statements will be realised. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Neither Actinogen nor any other entity or person in or associated with Actinogen guarantee any return (whether capital or income) or generally the performance of Actinogen or the price at which its securities may trade. Any investment in Actinogen is subject to investment risks including the possibility of loss of capital invested and no return of income or payment of any dividends.

To the maximum extent permitted at law, Actinogen and all of its representatives, directors, officers, partners, employees or professional advisers (**Parties**) exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), the Parties do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this presentation or any accompanying, previous or subsequent material or presentation.

Actinogen snapshot

Actinogen Medical (ASX:ACW) is a public company developing Xanamem^{®1}; a novel small molecule for cognitive impairment



Founded on excellent science

- ✓ 2014 in-license of Xanamem mid-Phase 1 from University of Edinburgh
- ✓ Designed to lower intracellular cortisol levels in the brain
- ✓ Strong scientific rationale for treatment of cognitive impairment and related symptoms



Focus on generating clinical data in multiple diseases

- ✓ Open IND(s), >200 subjects and patients treated
- ✓ Negative Phase II study in Alzheimer's Disease, likely due to short duration of 12 weeks
- ✓ Three new Phase II studies being launched



Fully funded for next stage

- ✓ AU\$15m in bank
- ✓ Sufficient to fund Mild Cognitive Impairment due to Alzheimer's disease POC study, Fragile X POC, 3rd indication POC




Strong & durable IP

- ✓ Composition of matter to 2031, 5-year extensions 2036
- ✓ New manufacturing and other patents provide additional protection

Xanamem - small molecule drug with a novel mechanism of action

Xanamem is a brain-penetrant 11 β -HSD1 small molecule enzyme inhibitor; designed to inhibit excessive cortisol production in the brain




Xanamem snapshot

Small molecule, once daily, with safety and rapid onset of cognitive improvement demonstrated in humans

	Xanamem exhibits favourable characteristics	✓ High levels of brain target engagement demonstrated ✓ Favourable pharmaceutical properties across multiple domains ✓ Low drug interaction potential
	Substantial clinical data	✓ >200 subjects or patients treated, >120 for 12 weeks ✓ Significant preclinical and clinical data generated ✓ Safe and well tolerated
	Attractive target indications	✓ Significant opportunity in Mild Cognitive Impairment due to Alzheimer's disease ✓ Strong scientific rationale for Fragile X Syndrome program with FDA Rare Paediatric Disease designation granted ✓ 3rd indication pending
	CMC and nonclinical progressing well	✓ Manufacturing scale up in process, low 10mg daily dose ✓ GLP nonclinical testing in advanced stages

Clinical pipeline for Xanamem

Major clinical trials to be initiated in CY21 targeting brain penetration, improved cognition and other benefits





Significant cognitive efficacy signal achieved


Phase 1 randomized, placebo-controlled XanaHES study demonstrated clinically and statistically significant cognitive efficacy signals¹

Cognitive Evaluation (Test)	p value			Treatment Effect Size: Cohen's d			
	All	Male	Female	Week 2	Week 4	Week 8	Week 12
Working Memory (One Back Test)	<0.01*	<0.01*	0.03*	0.64#	0.78#	0.64#	0.83 ^Δ
Visual Attention (Identification Test)	0.05*	0.04*	0.60	0.19	0.67#	0.62#	0.67#
Psychomotor Function (Detection Test)	0.09 ^Δ	0.94	0.13	0.47	0.65#	1.12 ^Δ	0.76#
Paired Associate Learning (CPAL Test)	0.21	0.34	0.49	0.87 ^Δ	0.01	0.66#	0.08
Memory (CPAL – Delayed Test)	0.50	0.55	0.21	0.34	0.23	0.06	0.48
Visual Learning (One Card Learning Test)	0.92	0.41	0.64	0.11	0.12	0.60#	0.19

Timecourse of cognitive improvement in XanaHES¹


Working memory (One Back Test)

Strongly statistically significant result




Visual attention (Identification Test)

Statistically significant result



Psychomotor function (Detection Test)

Good trend to a positive result



Treatment Group


— Xanamem 30pts — Placebo 12 pts

Clinically significant efficacy results in 3/6 domains tested – all domains trended positive



Review of data supports a low Xanamem dose

Human Target Occupancy Study PET data demonstrates consistent suppression of enzyme activity at 5mg Xanamem doses and above




PET data demonstrates that Xanamem extensively binds to the 11β -HSD1 enzyme throughout the brain, with high post-treatment effects (absence of colour) after 7 days at all doses, including a 5mg Xanamem dose.

This is consistent with full hormonal pharmacodynamic activity seen with 10mg Xanamem in clinical trials.

Actinogen is seeking to confirm the minimum effective dose of Xanamem to use going forward.



Bridging positive Phase I cognition data to Alzheimer's patients





XanaMIA Phase II trial to commence mid CY21

Targeting the first stage of Alzheimer's disease

XanaMIA - Part A

- **Healthy older subjects** - with normal cognition, ≥50 years of age (same as XanaHES trial)
- **Endpoints and testing criteria** - to leverage modern and highly sensitive cognition tests (Cogstate, iDSST)
- **Dose ranging** - at 5mg, 10mg Xanamem once daily

Dose ranging study to healthy elderly to **confirm minimum effective dose of Xanamem**

XanaMIA - Part B

- Targeting subjects with **mild cognitive impairment** due to Alzheimer's disease (using positive serum biomarkers)
- Bridging to patients with **modern and sensitive cognition tests** (Cogstate, iDSST) from Part A
- Introducing other cognitive and functional endpoints that have been **accepted by regulators for later studies**

Phase II trial to **assess efficacy of Xanamem** in patients with MCI due to AD

Strong Leadership and Management

Leadership has a strong track record in drug development and extensive commercial experience

Experienced Board of Directors..



Dr. Geoff Brooke

Chairman

MBBS; MBA



- **30+ years experience** in the healthcare investment industry
- Founder and MD of Medvest Inc and GBS Venture Partners



Dr. George Morstyn

Non-Executive Director

MBBS; PhD; FRACP; MAICD



- **25+ years experience** in biotech investment and drug development
- Board member of Cancer Therapeutics and SymBio; Former Senior VP and CMO at Amgen



Mr. Malcolm McComas

Non-Executive Director

BEC, LLB; FAICD; SF Fin



- **25+ years experience** in the financial services industry
- Chairman of Pharmaxis and Fitzroy River Corporation; formerly senior leadership roles in investment banking

...with a talented management team in place



Dr. Steven Gourlay

CEO & MD

MBBS; PhD; MBA



- **30+ years experience** in the development of novel therapeutics and has significant regulatory experience interacting with FDA and EMA
- Formerly the founding Chief Medical Officer at US-based Principia Biopharma Inc., and Senior Director of Genentech



Jeff Carter
Chief Financial Officer

B. Fin Admin;
M. App. Fin; CA



Tamara Miller
Vice President Drug Development & Strategy

M.Med; M.PharmSci;
BSc; MSc; PMP; CPPM



Kate Lingard
Associate Director of Clinical Operations

B. BiotInno (Hons)

See full team and bios at: <https://actinogen.com.au/our-company/#about-us>

Global Advisory Boards

World-leading, premier academics in Alzheimer's Disease¹

Xanamem Clinical Advisory Board

*Positions Xanamem at the forefront
of drug development*



Prof. Craig Ritchie
Chair



THE UNIVERSITY
of EDINBURGH



**Prof. Colin
Masters AO**



**Prof. Jeffrey
Cummings**



**Cleveland
Clinic**



**Prof. Alan
Boyd**



**Prof. Jonathan
Seckl**



THE UNIVERSITY
of EDINBURGH



**Prof. Brian
Walker**



**Newcastle
University**



**Prof. Scott
Webster**



THE UNIVERSITY
of EDINBURGH

Corporate overview


Recent strong interest in ACW stock

Trading Information

52 week high	A\$0.099
52 week low	A\$0.017
Number of shares	1,660.6M
Market capitalisation (24 May 2021)	A\$159.4M
Net cash ¹	A\$15.2M

Major Shareholders

BVF Partners	14.4%
Steven Gourlay ³	3.8%
Edinburgh Technology Fund	2.9%



Share Price Performance² (YTD)



Source: IRESS

1. Cash as at 31 March 2021

2. Volume traded on 5 Feb 2021 of 283.1M has been capped due to differences in volume.

3. Holding based on loan plan shares (~48M), and shares acquired in the 2021 shortfall placement (~15M)

Significant value upside for Actinogen

Accelerate clinical development

- Expand pipeline with additional indications and clinical trials, providing multiple shots on goal
- Generate data to optimise potential partnership discussions
- Scale up and optimise manufacturing to prepare for commercially viable, large scale production

Potential commercial & corporate value



Pharma engagement

- Actinogen is actively engaging with potential future partners on a regular basis
- High level of commercial interest and deal flow
- Recent AD deal value of ~US\$1B (US\$160M - US\$2.4B range)¹

RPDD

Transferable PRV voucher

- Eligible through RPDD recently granted by FDA²
- Recently traded for US\$100M-US\$125M³



High company valuations

- Companies with a lead asset in phase II or III development for AD have valuations between ~US\$350M-\$1.4B⁴

1. US\$1B based on the average disclosed values of 13 major global pharmaceutical deals (Oct 2018 to Mar 2020) considered to have material interest in AD (Source: Bio-Link analysis)

2. Eligible for a transferable (including by sale) Priority Review Voucher under Rare Paediatric Disease Designation from the FDA (if Xanamem is first registered in the US for FXS)

3. Potential to receive a Priority Review Voucher (PRV) upon approval in FXS – (Source: PRV value adapted from FDA website; Company press releases; priorityreviewvoucher.org)

4. Vivoryon Therapeutics, phase IIb AD lead asset (EURONEXT Amsterdam: 292 euro / ~US\$350m); Athira Pharma, phase II AD lead asset (NASDAQ GS:US\$610m); Cortexyme, phase III AD lead asset (NASDAQ GS:US\$1.1B) and same drug in phase II for periodontal disease and Parkinson's disease; Cassava Sciences, AD lead asset phase III-ready (NASDAQ GS:US\$1.41B). All companies' value primarily attributed to their lead AD asset. Market capitalisations as of 16/4/2021.

Next steps and key catalysts

Strong balance sheet, good clinical cognitive activity and safety from which to launch multiple Phase II trials

☐ Clinical trials to commence in 2021*

- XanaMIA Part A data expected in H1 2022
- XanaFX data expected by early 2023
- XanaMIA Part B data expected 2023

☐ Pursue other high priority indications

- Leverage strong academic, grant collaborations
- Start 3rd indication late 2021/early 2022

☐ Expand team to pursue aggressive timelines

☐ Publications and scientific presentations

